In an in vitro model of amyotrophic lateral sclerosis (ALS), PACAP treatment of motor-neuron like cells mitigated cell death with its mechanism of action being the epidermal growth factor receptor (EGFR) and matrix metallopeptidase-2 (MMP-2) axis [96]. Here, ADCYAP1 is linked to amyotrophic lateral sclerosis.